Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL1+CD33 CAR-T in Relapsed/Refractory AML
NCT05467254Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL1-CD33 compound CAR T cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Changes in cytokine level after CLL1+CD33 CAR-T infusion at 2 years and The change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number in patients after infusion at 2 years. Status: unknown.
02
Drugs
CLL1-CD33 compound CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05467254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467254.